Strategic Partnership Buzz: Recent chatter on X about Olema Pharmaceuticals (OLMA) has exploded following the announcement of a strategic collaboration in immuno-dermatology. Posts highlight a staggering pre-market surge of over 60%, with many pointing to fresh catalysts driving momentum. The excitement centers on potential pipeline advancements and market reactions.
Drug Development Momentum: Discussions on X also focus on OLMA’s progress with its breast cancer drug, Palazestrant, and a potential Pfizer collaboration. Several users noted Phase 3 trial momentum as a key driver of interest. Additionally, some linked the stock’s rally to a rival’s trial update, fueling further speculation.
Market Sentiment Spike: The volume of posts and engagement on X reflects a sharp uptick in attention, with many describing the stock as a breakout candidate. Traders appear fixated on price zones and upcoming milestones. The tone across these discussions remains highly optimistic.
Note: This discussion summary was generated from an AI condensation of post data.
Olema Pharmaceuticals Insider Trading Activity
Olema Pharmaceuticals insiders have traded $OLMA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $OLMA stock by insiders over the last 6 months:
- CYRUS HARMON has made 0 purchases and 4 sales selling 25,000 shares for an estimated $204,840.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Olema Pharmaceuticals Hedge Fund Activity
We have seen 60 institutional investors add shares of Olema Pharmaceuticals stock to their portfolio, and 75 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MPM BIOIMPACT LLC removed 2,378,762 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $23,288,079
- WOODLINE PARTNERS LP removed 1,288,000 shares (-36.7%) from their portfolio in Q3 2025, for an estimated $12,609,519
- MILLENNIUM MANAGEMENT LLC removed 939,636 shares (-73.9%) from their portfolio in Q3 2025, for an estimated $9,199,036
- SILVERARC CAPITAL MANAGEMENT, LLC added 933,541 shares (+inf%) to their portfolio in Q3 2025, for an estimated $9,139,366
- KINGDON CAPITAL MANAGEMENT, L.L.C. added 854,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,360,659
- BALYASNY ASSET MANAGEMENT L.P. added 693,179 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,786,222
- SOLEUS CAPITAL MANAGEMENT, L.P. added 619,874 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,068,566
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Olema Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $OLMA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 10/08/2025
- Oppenheimer issued a "Outperform" rating on 09/03/2025
- Citigroup issued a "Buy" rating on 08/12/2025
To track analyst ratings and price targets for Olema Pharmaceuticals, check out Quiver Quantitative's $OLMA forecast page.
Olema Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $OLMA recently. We have seen 5 analysts offer price targets for $OLMA in the last 6 months, with a median target of $22.0.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $28.0 on 10/20/2025
- Brad Canino from Guggenheim set a target price of $20.0 on 10/08/2025
- Matthew Biegler from Oppenheimer set a target price of $22.0 on 09/03/2025
- Anupam Rama from JP Morgan set a target price of $29.0 on 08/14/2025
- Yigal Nochomovitz from Citigroup set a target price of $21.0 on 08/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
